Arthur Sands | BiotechTV

top of page

Dec 10

ASH 2024: Nurix Therapeutics' CEO Arthur Sands talks BTK degradation vs inhibition and the company's broader pipeline of degraders

He discusses Nurix's clinical data set that was presented at ASH. Plus, the company's pipeline, including in the autoimmune space, and...

Talking BTK degraders with the CEO of Nurix Therapeutics at #ASH23

Dec 11, 2023

Company News

Talking BTK degraders with the CEO of Nurix Therapeutics at #ASH23

Arthur Sands elaborates on two programs Nurix presented updated data for at ASH and dives into the company's pipeline and partnerships.

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh